US2011281850A1PendingUtilityA1

Intracellular kinase inhibitors

44
Assignee: FLYNN GARY APriority: May 18, 2006Filed: Jul 7, 2011Published: Nov 17, 2011
Est. expiryMay 18, 2026(expired)· nominal 20-yr term from priority
Inventors:Gary A. FlynnSandra LeeMary FarisDavid BrandtSubrata Chakravarty
A61P 35/00A61P 37/06A61P 3/10A61P 37/00A61P 43/00A61P 7/02A61P 37/02A61P 7/04A61P 35/02A61P 7/06A61P 7/00A61P 25/02A61P 29/00A61P 25/00C07D 295/108A61K 31/538C07D 319/18C07D 211/10C07D 209/44C07D 333/56C07D 207/08C07D 401/06A61P 19/02A61P 1/02A61P 11/06A61K 31/5375A61P 17/00A61K 31/40A61K 31/47A61K 31/495A61P 1/04A61K 31/33C07D 265/36A61K 31/137C07D 295/215A61K 31/4035C07D 307/80C07D 207/14C07D 307/52A61P 13/12A61K 31/445C07D 295/192C07D 317/54C07D 401/04A61P 21/00C07D 211/30C07D 217/04A61K 31/5377C07D 295/185C07D 211/26A61P 1/16
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.

Claims

exact text as granted — not AI-modified
1 . A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of an interleukin-2 inducible tyrosine kinase (ITK) inhibitor. 
     
     
         2 . The method of  claim 1  wherein the cancer is a blood cell malignancy. 
     
     
         3 . The method of  claim 2  wherein the blood cell malignancy is a lymphoma. 
     
     
         4 . The method of  claim 3  wherein the lymphoma is Hodgkin's lymphoma. 
     
     
         5 . The method of  claim 3  wherein the lymphoma is anon-Hodgkin's lymphoma. 
     
     
         6 . The method of  claim 5  wherein the non-Hodgkin's lymphoma is selected from the group consisting of cutaneous T cell lymphoma, diffuse large cell lymphoma, HTLV-1 associated T lymphoma, nodal peripheral T cell lymphoma, extranodal peripheral T lymphoma, central nervous system lymphoma, cutaneous T cell lymphoma (CTCL), and AIDS-related lymphoma. 
     
     
         7 . The method of  claim 2  wherein the blood cell malignancy is a leukemia. 
     
     
         8 . The method of  claim 7  wherein the leukemia is selected from the group consisting of acute lymphocytic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, T prolymphocytic leukemia, adult T cell leukemia (ATL), and hairy cell leukemia. 
     
     
         9 . The method of  claim 2  wherein the blood cell malignancy is a mast cell malignancy. 
     
     
         10 . The method of  claim 5  wherein the non-Hodgkin's lymphoma is CTCL, and the CTCL is mycosis fungoides. 
     
     
         11 . The method of  claim 5  wherein the non-Hodgkin's lymphoma is CTCL, and the CTCL is Sezary syndrome. 
     
     
         12 . The method of  claim 1  wherein cells of the cancer express ITK. 
     
     
         13 . The method of  claim 1  wherein cells of the cancer express Bruton's tyrosine kinase (BTK).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.